South San Francisco, CA October 11, 2023 Press Release Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based…
Tag: Multiple Sclerosis
Genentech Presenting at the 9th Joint ECTRIMS-ACTRIMS Meeting (European and Americas Committees for Treatment and Research in Multiple Sclerosis)
South San Francisco, CA October 2, 2023 Press Release Genentech to Present New Key Clinical and Real-world Data at ECTRIMS-ACTRIMS 2023 Showcasing Strength of Long-term Outcomes in MS and NMOSD Late-breaking results from Phase III trial of Ocrevus (ocrelizumab) subcutaneous…
Genentech Announces Industry-Leading Brain Health Research / Neuroscience at AAN 2023 Annual Meeting
South San Francisco, CA April 23, 2023 Press Release Genentech Announces Industry-Leading Brain Health Research Collaborations and Latest Data Across Neuroscience Medicines at AAN 2023 Annual Meeting Roche, Genentech and partners embark on global prevalence research, trend-spotting with digital analysis,…
New OCREVUS (Ocrelizumab) Data at ECTRIMS Advance Clinical Understanding of Underlying Progression in Multiple Sclerosis
South San Francisco, CA October 26, 2017 Genentech Press Release New OCREVUS (Ocrelizumab) Data at ECTRIMS Advance Clinical Understanding of Underlying Progression in Multiple Sclerosis Data show superiority of OCREVUS compared to Rebif (interferon beta-1a) in significantly reducing disability Progression…
New Data at EAN Show Genentech’s Ocrevus (Ocrelizumab) Significantly Reduced Multiple Measures of Disease Progression in Relapsing and Primary Progressive Multiple Sclerosis
South San Francisco, CA June 23, 2017 Genentech Press Release OCREVUS increased the number of patients with relapsing MS (RMS) and primary progressive MS (PPMS) who maintained No Evidence of Progression or Active Disease (NEPAD) versus Rebif® (interferon beta-1a)…
FDA Approves Genentech’s OCREVUS™ (Ocrelizumab) For Relapsing and Primary Progressive Forms of Multiple Sclerosis
South San Francisco, CA March 29, 2017 Genentech Press Release First and only approved disease-modifying therapy for primary progressive form of multiple sclerosis (PPMS) – one of the most disabling forms of multiple sclerosis (MS) An…
Genentech to Present New Data at AAN Showing Superior Efficacy of Investigational Medicine Ocrelizumab Versus Comparators on Disease Activity and Progression in Two Forms of Multiple Sclerosis
South San Francisco, Ca April 12, 2016 Genentech Press Release New analyses showing superior efficacy of ocrelizumab across clinical and subclinical outcomes compared with interferon beta- 1a (Rebif®) in people with relapsing multiple sclerosis (MS) and compared with placebo…